An interventional study of Point-of-care testing (POCT) -Patient participants and Point-of-care testing (POCT) - Healthy control participants in Sickle Cell Disease, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in Mozambique. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by St. Jude Children's Research Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital — 15 open to participants now, 17 under way, none of them phase 3. Anemia, Sickle Cell · St. Jude Children's Research Hospital.
Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, this one has the largest planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, reaches primary completion later than 13 of the 16 other live ones, and was the 45th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →15 of the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital are open now, in 2 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
St. Jude Children's Research Hospital · Sites in United States
Ages 10–18 · Women only · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 8–17
St. Jude Children's Research Hospital · Sites in United States
Ages 42 mo–78 mo
St. Jude Children's Research Hospital · Sites in United States
Ages 18–24
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,750 is above the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 45 across the 22 interventional studies, 88 across the 23 observational. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
4 of the studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03353584St. Jude Children's Research HospitalEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease | 2026-11 |
| NCT06477289St. Jude Children's Research HospitalPeripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease | 2027-06 |
| NCT07226219St. Jude Children's Research HospitalMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | 2027-07-01 |
| NCT05583721St. Jude Children's Research HospitalRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overarching goal of this study is to evaluate the feasibility of a new methodology that combines three multi-level implementation strategies to optimize the population-level uptake of essential evidence-based, standard of care treatments for infants with sickle cell disease (SCD) in low-resource settings. The study will be done in Mozambique.
This prospective mixed-methods hybrid effectiveness-implementation feasibility study will evaluate the feasibility and effectiveness of an implementation strategy package designed to improve early diagnosis and care entry for children born with sickle cell disease (SCD) in rural, low-resource settings. The implementation strategy package includes three components: 1) integration of essential products into national supply chain systems, 2) integration of systematic newborn screening using point-of-care-testing into clinical site workflows and 3) linkage of children who screen positive to a PEN-Plus Non-Communicable Disease (NCD) clinic for longitudinal care. Participants will be tracked longitudinally to evaluate protocol adoption over time and clinical outcomes among participating children at 2 years of age.
Primary Objective
Secondary Objectives (Micro level):
Secondary Objectives (Meso level)
Secondary Objective (Macro level)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Children participants will fall into one of two categories:
Exclusion Criteria:
Children participants:
Healthy control participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All infants between birth and 6.0 months of age who were screened through the UNIQUE study and tested positive for SCD (HbSS, HbSC, or other form of SCD) or had indeterminate results.
Other: Point-of-care testing (POCT) -Patient participants
Infants between birth and 6.0 months of age who screen negative for SCD (HbAA) through the UNIQUE study or tested positive for sickle cell trait (HbAS).
Other: Point-of-care testing (POCT) - Healthy control participants
Healthcare staff ages ≥18 years working at secondary-level facilities involved in the UNIQUE study.
Other: Context Assessment for Community Health (COACH) survey · Other: Semi-structured interview
Administrative professionals with experience working in or around the national supply chain systems in Mozambique to support procurement, importation, customs clearance, storage, and in-country distribution of medical products.
Other: Semi-structured interview
Administrative professionals with experience working in the national public health system (e.g., Ministry of Health, MISAU) who oversee the delivery of health services to infants in-country, such as neonatal testing and vaccination programs.
Other: Semi-structured interview
Infants will be screened for Sickle Cell Disease using with point-of-care testing (POCT).
Infants will be screened for Sickle Cell Disease using with point-of-care testing (POCT) and prospectively monitored for survival.
The COACH survey will collect quantitative data on eight contextual factors that impact a site's ability to implement evidence-based interventions.
Interview questions will revolve primarily around the current process for SCD screening and care referrals, factors impacting newborn care delivery and screening, and challenges to integrating SCD newborn screening and care referral into standard care delivery.
Percentage of eligible population screened for Sickle Cell Disease
Time frame: 3 years
Percentage of new SCD cases linked to care
Time frame: 3 years
Comparison of under-2 mortality between participants with SCD whom received longitudinal care and participants who screened negative for SCD
The primary outcome measure will be 'Alive and in care: Yes or No'.
Time frame: 2 years post-screening and therapy
Percentage of SCD cases retained in care by 2 years of age
Time frame: 2 years post-screening and therapy
Percentage of eligible secondary-level clinical wards implementing systematic screening and linkage to longitudinal care for new SCD cases
Time frame: 3 years
Percentage of eligible health facility staff participants in secondary-level clinical wards implementing systematic screening and linkage to longitudinal care for new SCD cases
Time frame: 3 years
Comparison of SCD Screening Performance Results from Initial point-of-care (POCT), Gazelle, and Hemoglobin Fractionation
Investigators will estimate the sensitivity (proportion of diseased subjects that yield a positive test result) and specificity (the proportion of non-diseased subjects that yield a negative test result) of the POCT for detecting SCD compared to the gold standard with basic proportions.
Time frame: 3 years
Cost-Effectiveness of Integrating SCD Consumables into National Supply Chains
The standard formula known as incremental cost-effectiveness ratios (ICERs) will be used. ICER is a summary statistic used in economic evaluations to compare the relative value of different healthcare interventions. It is scored by comparing the resulting cost-per-QALY against a predefined threshold, where lower ICERs indicate better value.
Time frame: 2 to 5 years
Cost-Effectiveness of POCT for Early SCD Diagnosis
The standard formula known as incremental cost-effectiveness ratios (ICERs) will be used. ICER is a summary statistic used in economic evaluations to compare the relative value of different healthcare interventions. It is scored by comparing the resulting cost-per-QALY against a predefined threshold, where lower ICERs indicate better value.
Time frame: 2 to 5 years
Cost-Effectiveness of Decentralized PEN-Plus SCD Management
The standard formula known as incremental cost-effectiveness ratios (ICERs) will be used. ICER is a summary statistic used in economic evaluations to compare the relative value of different healthcare interventions. It is scored by comparing the resulting cost-per-QALY against a predefined threshold, where lower ICERs indicate better value.
Time frame: 2 to 5 years
Frequency of SCD Supply Stockouts at Study Sites
Time frame: 5 years
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Aug 2031, 59 months after the start.
Of 165 non-industry interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 59 months is above that.
Counting every sponsor, half of 173 studies reached it within 28 months; a quarter within 15 and three quarters within 49.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Jude Children's Research Hospital →